Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Circulating tumor DNA as a novel prognostic indicator

Nature Medicine volume 28, pages 2255–2256 (2022)Cite this article

Subjects

Circulating tumor DNA (ctDNA) informs predictive biomarkers in non–small-cell lung cancer, but the presence of ctDNA itself could also be a prognostic indicator.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Prognostic value of ctDNA in stage IV NSCLC and factors contributing to its release and clearance.

References

  1. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 (accessed September 2022).

  2. Lindeman, N. I. et al. J. Thorac. Oncol. 13, 323–358 (2018).

    Article  CAS  PubMed  Google Scholar 

  3. Planchard, D. et al. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 29, iv192–iv237 (2018).

    Article  CAS  Google Scholar 

  4. Jee, J. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02047-z (2022).

    Article  PubMed  Google Scholar 

  5. Paweletz, C. P., Lau, C. J. & Oxnard, G. R. JCO Precis. Oncol. 3, 1–3 (2019).

    PubMed  Google Scholar 

  6. Gray, J. E. et al. Clin. Cancer Res. 25, 6644–6652 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Rolfo, C. et al. J. Thorac. Oncol. 16, 1647–1662 (2021).

    Article  CAS  PubMed  Google Scholar 

  8. Bettegowda, C. et al. Sci. Transl. Med. 6, 224ra24 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Serrano, C. et al. BMC Cancer 20, 1–12 (2020).

    Article  Google Scholar 

  10. Schrag, D. et al. Ann. Oncol. 33, S417–S426 (2022).

    Article  Google Scholar 

  11. Abbosh, C. et al. Nature 545, 446–451 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kustanovich, A., Schwartz, R., Peretz, T. & Grinshpun, A. Cancer Biol. Ther. 20, 1057–1067 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank A. Wren and J. Carmona for editorial assistance. A.V. acknowledges the FERO Foundation for their funding support to the DIAMAV (Advanced Molecular Diagnostics) Program and the Cellex Foundation for providing research facilities and equipment.

Author information

Authors and Affiliations

  1. Cancer Genomics Lab, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

    Ana Vivancos

  2. Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

    Josep Tabernero

  3. Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

    Josep Tabernero

Authors
  1. Ana Vivancos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josep Tabernero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana Vivancos.

Ethics declarations

Competing interests

A.V. reports personal financial interest in the form of scientific consultancy roles for Bayer, Bristol-Myers Squibb, Guardant Health, Incyte, Merck Serono, Novartis and Roche. J.T. reports personal financial interest in the form of scientific consultancy roles for Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Tessa Therapeutics and TheraMyc, as well as stock holdings in Oniria Therapeutics and also educational collaboration with Imedex/HMP, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vivancos, A., Tabernero, J. Circulating tumor DNA as a novel prognostic indicator. Nat Med 28, 2255–2256 (2022). https://doi.org/10.1038/s41591-022-02068-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-02068-8

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer